Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Fineline Cube May 12, 2026
Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Fineline Cube May 12, 2026
Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Fineline Cube May 12, 2026
Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026
Company Drug

Luye Pharma’s Rotigotine Microspheres Meet Phase III Goals in Parkinson’s Study

Fineline Cube Jul 20, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for rotigotine...

Company Drug

Eli Lilly’s Retevmo Wins Special Approval in China’s Lecheng Medical Pilot Zone

Fineline Cube Jul 20, 2022

Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...

Company Deals

Attec Completes Pre-Series A Financing with Sequoia China Backing Protein Degradation Tech

Fineline Cube Jul 19, 2022

China-based biotech startup Attec has completed a pre-Series A financing round, with its protein degradation...

Company Drug

Innovent Biologics’ Mazdutide Meets Phase II Goals in Type 2 Diabetes Study

Fineline Cube Jul 19, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that its Phase II study of mazdutide (IBI362/OXM3)...

Company Deals

Digital Precision Medicine Raises Hundreds of Millions in Series B Financing for Molecular Imaging Innovation

Fineline Cube Jul 19, 2022

China-based Digital Precision Medicine (DPM), a molecular imaging and fluorescence endoscopy manufacturer, has reportedly raised...

Company Drug

Sihuan Pharma’s Fourth-Gen Insulin Degludec NDA Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its New Drug Application (NDA)...

Company Drug

Sihuan Pharma’s Anaprazole Enters Phase II Study for Reflux Esophagitis

Fineline Cube Jul 19, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co.,...

Company R&D

Takeda Opens R&D Asia-Pacific Headquarters in Shanghai to Boost Drug Development

Fineline Cube Jul 19, 2022

Japan’s Takeda Pharmaceutical Co., Ltd has inaugurated its R&D Asia-Pacific headquarters in Pudong, Shanghai. The...

Company Deals

Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development

Fineline Cube Jul 19, 2022

Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has...

Company Drug

Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs

Fineline Cube Jul 19, 2022

Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...

Company Medical Device

Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...

Company Drug

Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis

Fineline Cube Jul 19, 2022

Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...

Company Drug

Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study

Fineline Cube Jul 19, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...

Company Deals

Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China

Fineline Cube Jul 19, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...

Company Drug

Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China

Fineline Cube Jul 19, 2022

Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...

Company Deals

Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation

Fineline Cube Jul 19, 2022

China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...

Drug

HutchMed Initiates Phase I Study of CD47 Monoclonal Antibody HMPL-A83 in China

Fineline Cube Jul 19, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study...

Company Deals

Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China

Fineline Cube Jul 19, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...

Company Deals

Fermion Secures Series B Financing to Advance AI-Driven Drug Development

Fineline Cube Jul 18, 2022

Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...

Company Deals

Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform

Fineline Cube Jul 18, 2022

Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...

Posts pagination

1 … 645 646 647 … 663

Recent updates

  • Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties
  • Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304
  • CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer
  • AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions
  • CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.